International Scholarly Research Notices

Review Article

The Impact of Histologic Variants on FSGS Outcomes

Table 2

Summary of the main studies evaluating patient characteristics at presentation and renal outcomes of different FSGS variants.


Study (patients)	Age (years)	Ethnicity	Baseline nephrotic syndrome (%)	Baseline renal function	Remission (%)	Renal outcomes

Chun et al. 2004 [14] ()	NOS/perihilar: 40 ± 17 Cell + coll: 38 ± 16 Tip: 53 ± 17	% Black race NOS/perihilar: 47 Cell + coll: 72 Tip: 44	NOS/perihilar: 75 Cell + Coll: 84 Tip: 100	Cr (mg/dl): NOS: 1.4 ± 0.5 Cell + coll: 1.9 ± 1.4 Tip: 1.6 ± 0.8	CR/PR/CR + PR NOS/perihilar: 16.7/13.9/30.6 Cell + coll: 15/30/45 Tip: 45.4/18.2/63.6	% ESRD NOS/perihilar: 25 Cell + coll: 43 Tip: 27

Stokes et al. 2006 [15] ()	All: 37.7 ± 1.3 NOS: 32.5 ± 2.0 Cell: 48.8 ± 4.9 Coll 31.2 ± 2.3 Tip: 47.5 ± 2.3	% Black race All: 31.5 NOS: 28.9 Cell: 31.8 Coll: 53.6 Tip: 13.8	All: 75.5 NOS: 52.9 Coll: 85.5 Cell: 86.4 Tip: 94.8	Cr (mg/dl): All: 2.3 ± 0.2 NOS: 1.9 ± 0.2 Cell: 1.9 ± 0.3 Coll: 3.9 ± 0.6 Tip: 1.5 ± 0.1	CR/PR/CR + PR All: 27.3/11.2/38.5 NOS: 24.1/14.5/38.6 Cell: 38.9/5.5/44.4 Coll: 7.5/5.7/13.2 Tip: 60.6/15.2/75.8	% ESRD All: 30.7 NOS: 34.5 Cell: 27.8 Coll: 65.3 Tip: 5.7

Thomas et al. 2006 [16] ()	All: 49 ± 15 NOS: 50 ± 15 Cell: 45 ± 13 Coll: 38 ± 12 Tip: 54 ± 13 Perihilar: 50 ± 16	% Black race All: 40 NOS: 43 Cell: 33 Coll: 91 Tip: 15 Perihilar: 29	All: 70 NOS: 67 Cell: 75 Coll: 83 Tip: 88 Perihilar: 55	Cr (mg/dl): All: 2.1 ± 2.0 NOS: 2.1 ± 1.8 Cell: 2.5 ± 1.7 Coll: 3.1 ± 3.8 Tip: 1.5 ± 0.9 Perihilar: 2.0 ± 1.4	CR/(CR or PR) All: 19/24 NOS: 13/16 Cell: 33/33 Coll: 14/18 Tip: 50/53 Perihilar: 10/19	% Renal survival⁺ 3-year All: 67 NOS: 65 Cell: NA Coll: 33 Tip: 76 Perihilar: 75

Paik et al. 2007 [17] ()	All: 6.7 ± 3.5	N/A	All: 92.4	Cr (mg/dl): All: 0.77 ± 0.50	CR/PR All: 39.1/15.2/54.3	% ESRD All: 21.7% % Renal survival^‡ 5-year: 84 10-year: 64 15-year: 53

Silverstein and Craver 2007 [18] ()	All: 10.9 ± 0.9	% Black race All: 80.5%	All: 63.4 NOS: 55.6 Cell: 81.8 Coll: 54.5	eGFR (ml/min/1.73 m²) All: 105.4 ± 4.6 NOS: 116.5 ± 4.9 Cell: 107.6 ± 7.2 Coll: 88.2 ± 10.7	CR + PR All: 71 NOS: 72.2 Cell: 75 Coll: 45.4	% CKD stage 5 NOS: 0 Cell: 0 Coll: 18.2

Deegens et al. 2008 [19] ()	All: 49 ± 16 NOS: 51 ± 17 Collapsing: 63 ± 18 Tip: 44 ± 16 Perihilar: 50 ± 12	% Dutch descent: All: 96 NOS: 93 Collapsing: 100 Tip: 97 Perihilar: 96	% NS: All: 63 NOS: 57 Collapsing: 80 Tip: 97 Perihilar: 25	Cr (mg/dl): All: 1.7 ± 1.1 NOS: 1.99 ± 1.3 Collapsing: 2.2 ± 1.6 Tip: 1.3 ± 0.9 Perihilar: 1.6 ± 0.99	CR + PR All: 44 NOS: 38 Collapsing: 50 Tip: 57 Perihilar: 25	% Renal survival^~ 5-year All: 66 NOS: 63 Collapsing: 30 Tip: 78 Perihilar: 55

D’Agati et al. 2013 [20] ()	NOS: 13 Coll: 16.5 Tip: 15	% Black race: NOS: 39 Coll: 63 Tip: 14	% severe/intermed. nephrosis^*: NOS: 69 Tip: 93 Coll: 94	Cr (mg/dl): NOS: 0.86 ± 0.61 Tip: 0.84 ± 0.43 Coll: 1.33 ± 0.50	N/A	% ESRD at 3 yrs NOS: 20 Coll: 47 Tip: 7

Intermediate nephrosis = U p/c > 2 and ≤6 g/g or serum albumin ≥1.5 and <2.5 g/dl; severe nephrosis = Up/c > 6 g/g or serum albumin <1.5 g/dl.
⁺Renal failure = sustained doubling of the serum creatinine or initiation of chronic dialysis or kidney transplantation.
^‡Renal survival = measured from date of presentation to diagnosis of CRF.
^~Renal failure = sustained increase of the serum Cr concentration of >50% from baseline or development of ESRD.